Evidence map›Paper›PMID 41626170›Full record

ArticleFrontiers in oncology2025

Epithelial-myoepithelial carcinoma of the nasopharynx: cases report and literature review.

Wenju Xiong, Lijuan Yin, NaNa Wu, Zhongzheng Xiang, Jun Wang, Yuanyuan Zeng, Xiaoyuan Wei, Zelei Dai, Chenfeng Tan, Lei Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenju Xiong *Department of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Lijuan Yin *Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
NaNa Wu *Department of Oncology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
Zhongzheng XiangDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jun WangDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yuanyuan ZengDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiaoyuan WeiDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Zelei DaiDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Chenfeng TanDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Lei LiuDepartment of Head and Neck Oncology, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epithelial-myoepithelial carcinoma (EMCa) is a low-grade malignant tumor that occurs primarily in the salivary glands. Its occurrence in the nasopharynx is exceedingly rare. Due to its scarcity, there is currently a lack of standardized treatment protocols, and robust prognostic data remain limited. Methods: We report a case series of two patients with histopathologically confirmed nasopharyngeal EMCa, supplemented by a systematic literature review to summarize its clinicopathological characteristics, treatment modalities, and prognostic factors. Results: The two cases exhibited strikingly divergent outcomes. The first patient (Case 1) underwent surgical resection followed by adjuvant radiotherapy, achieving a complete clinical response and remaining disease-free at 31 months. In contrast, the second patient (Case 2) presented a markedly more aggressive profile, characterized by younger age, neurological symptoms, and an atypically high Conclusion: Our cases illustrate the heterogeneous clinical behavior of nasopharyngeal EMCa, ranging from indolent disease to aggressive progression. Our observations suggest that high

Indexed as

18F-FDGcase reportcomprehensive treatmentepithelial-myoepithelial carcinomalung metastasisnasopharynx

Identifiers

PMID41626170
PMCPMC12855145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.